SGP
SpyGlass Pharma, Inc.
Key Financials
Operating Income
$-41449000
↓ 53.2%
Net Income
$-39869000
↓ 36.7%
EPS (Diluted)
$-17.98
↓ 10.2%
Total Assets
$115.9M
↑ 396.9%
Total Liabilities
$10.2M
↓ 9.6%
Shareholders' Equity
$-98837000.00
↓ 63.4%
Cash & Equivalents
$96.4M
↑ 492.3%
Operating Cash Flow
$-32701000.00
↓ 48.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/14/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| 10-K | 3/26/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| SCHEDULE 13G | 2/17/2026 | View on SEC |
| SCHEDULE 13D | 2/17/2026 | View on SEC |
| SCHEDULE 13D | 2/13/2026 | View on SEC |
| SCHEDULE 13D | 2/13/2026 | View on SEC |
| 8-K | 2/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SGP |
| Company Name | SpyGlass Pharma, Inc. |
| CIK | 1778922 |
| Sector | Surgical & Medical Instruments & Apparatus |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 3841 |
| SIC Description | Surgical & Medical Instruments & Apparatus |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 949-284-6904 |